Publicaciones en las que colabora con Eugenio de Miguel Mendieta (36)

2024

  1. 18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry

    Journal of Clinical Medicine, Vol. 13, Núm. 20

  2. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine, Vol. 129, pp. 78-86

  3. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  4. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  5. Natural language processing to identify and characterize spondyloarthritis in clinical practice

    RMD Open, Vol. 10, Núm. 2

  6. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2023

  1. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register

    RMD Open, Vol. 8, Núm. 2

  2. Interobserver reliability of Masei index validation by a multicenter collaborative group of rheumatologists

    Rheumatology International, Vol. 42, Núm. 3, pp. 441-448

  3. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

2021

  1. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

2020

  1. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119

2019

  1. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 1, pp. 126-135

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  2. A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis

    Rheumatology International, Vol. 37, Núm. 8, pp. 1347-1356

  3. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

    Scientific Reports, Vol. 7

  4. Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort

    Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942

  5. Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 150-155

2016

  1. Differences between familial and sporadic early spondyloarthritis: Results from the ESPERANZA cohort

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 4, pp. 575-580

2014

  1. Analysis of two autoimmunity genes, IRAK1 and MECP2, in giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82